PARP1 and neoplasm: First tested in vitro, thedrug selectively targeted tumor cells with BRCA1,BRCA2, or PTEN gene alterations with 20-to more than 200-fold greater potency than existing PARP1/2 inhibitors (such asolaparib, rucaparib, and veliparib) (Shenet al., 2013).